X

Graft Versus Host Disease

Graft Versus Host Disease

Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation

Given before or after transplantation of donor blood or bone marrow cells, bendamustine has been shown to reduce the side effects of the transplant, including GvHD, where the donated cells...

Cancers
04/03/2021
Meibomian Gland Dysfunction in Ocular Graft vs. Host Disease: A Need for Pre-Clinal Models and Deeper Insights

Herein, the current state of the etiology and, pathophysiology of oGvHD based on existing pre-clinical models are reviewed.

International Journal of Molecular Sciences
03/29/2021
Ruxolitinib Before Allogeneic Hematopoietic Transplantation in Patients With Myelofibrosis on Behalf SFGM-TC and FIM Groups

This multicenter prospective phase 2 trial analyzes disease-free survival in myelofibrosis patients receiving ruxolitinib for 6 months before transplantation.

03/25/2021

Steroid-Dependent Acute GVHD After Allogeneic Hematopoietic Cell Transplantation: Risk Factors and Clinical Outcomes

Steroid-sensitive and steroid-dependent acute GvHD groups have similar risks of overall and nonrelapse mortality.

Blood Advances
03/03/2021
Efficiency of Human Monocyte-Derived Suppressor Cell-Based Treatment in Graft-versus-Host Disease Prevention While Preserving Graft-versus-Leukemia Effect

The objective of this study is to explore the therapeutic relevance of the HuMoSC in clinical conditions.

02/19/2021
Glycolytic Metabolism of Pathogenic T Cells Enables Early Detection of GVHD by 13C-MRI

Metabolic imaging is being increasingly used in the clinic and may be useful in the post-AHSCT setting for noninvasive early detection of GVHD.

Blood
01/07/2021
Mesenchymal Stem/Stromal Cells as a Valuable Source for the Treatment of Immune-Mediated Disorders

This paper discusses the therapeutic applications of MSC secretome and its biomedical aspects related to immune-mediated conditions.

Stem Cell Research & Therapy
03/18/2021
Interplay Between the Intestinal Microbiota and Acute Graft-Versus-Host Disease: Experimental Evidence and Clinical Significance

The current animal and human studies investigating the intestinal microbiota in aGVHD and the understanding of the influence and management of the microbiota in the clinic are reviewed herein.

Frontiers in Immunology
03/16/2021
Profiling Tissue and Biofluid miR-155-5p, miR-155*, and miR-146a-5p Expression in Graft vs Host Disease

In this study, investigators perform comprehensive expression profiling of miR-146a, miR-155, and miR-155* expression in aGvHD target tissue and biofluids and relate expression to post-HSCT outcome

Frontiers in Immunology
03/15/2021
FDA Grants Fast Track Designation to Neihulizumab for Acute GVHD

The FDA granted fast track designation to neihulizumab for treatment of steroid-refractory acute graft-versus-host disease, according to the agent’s manufacturer.

Healio
03/15/2021
GVHD Prophylaxis: Similar Outcomes With PTCy and ATG

A newer regimen is no more effective than an older regimen when both were compared for GVHD prophylaxis in patients who underwent reduced-intensity conditioning followed by a HSCT from...

Medscape
03/17/2021
Shulman Syndrome as a Manifestation of Severe Chronic Graft-versus-Host Disease

Chronic graft-versus-host-disease presenting as EF is a very rare manifestation of cutaneous GVHD.

Journal of Medical Case Reports
03/15/2021
Relationship of Donor Age and Relationship to Outcomes of Haploidentical Transplantation With Posttransplant Cyclophosphamide

This study seeks to identify factors to optimize the choice of haplo donors when using posttransplantation cyclophosphamide GVHD prophylaxis.

Blood Advances
03/04/2021
First-in-Human Phase 1 Trial of Induced Regulatory T Cells for Graft-versus-Host Disease Prophylaxis in HLA-Matched Siblings

Study investigators perform a phase 1, single-center, dose-escalation study to determine the safety profile of iTregs in adults with high-risk malignancy treated with...

Blood Advances
03/05/2021
Human Cytomegalovirus Infection: A Considerable Issue Following Allogeneic Hematopoietic Stem Cell Transplantation

This review summarizes the molecular mechanism and risk factors of HCMV reactivation following allo-HSCT, the diagnosis of CMV infection following allo-HSCT, prophylaxis and treatment...

Oncology Letters
02/23/2021
The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children

This study aims to evaluate the effectiveness of Ruxolitinib for acute/chronic graft-versus-host disease in children.

Drug Design, Development and Therapy
02/22/2021
Role of Antithymocyte Globulin in Matched Sibling Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

This study aims to investigate the safety and efficacy of antithymocyte globulin as a standardized part of GVHD prophylaxis in patients receiving MSD -PBSCT.

Medicine
02/26/2021
Polymorphisms in CXCR3 Ligands Predict Early CXCL9 Recovery and Severe Chronic GVHD

This study investigates the role of single-nucleotide polymorphisms of CXCL4, CXCL9, CXCL10, and CXCL11, and their day +28 serum levels, in cGVHD pathogenesis.

Blood Cancer Journal
02/27/2021
Mesenchymal Stem Cell Exosome-Derived miR-223 Alleviates Acute Graft-versus-Host Disease via Reducing the Migration of Donor T Cells

Study investigators perform expression profiling of exosome-miRNAs from human umbilical cord MSCs and murine compact bone MSCs to investigate their immunoregulation effects in aGvHD.

Stem Cell Research & Therapy
02/26/2021
Repurposing a Novel Anti-Cancer RXR Agonist to Attenuate Murine Acute GVHD and Maintain Graft-versus-Leukemia Responses

Study investigators have developed a novel pharmacological approach to inhibit graft-versus-host disease by activating retinoid X receptor in donor T cells.

Blood
02/25/2021
Noninvasive Tools Based on Immune Biomarkers for the Diagnosis of Central Nervous System Graft-vs-Host Disease

Currently, establishing a diagnosis of CNS-GVHD is challenging because the diagnostic criteria and diagnostic methods are not well defined and many confounding factors need to be ruled out.

World Journal of Clinical Cases
02/26/2021
A Phase 2 Trial of GVHD Prophylaxis With PTCy, Sirolimus, and MMF After Peripheral Blood Haploidentical Transplantation

Sirolimus and PTCy/MMF permit hematopoietic engraftment and result in low moderate/severe chronic GVHD rates and favorable survival.

Blood Advances
02/26/2021
Mesenchymal Stromal Cells as Prophylaxis for Graft-versus-Host Disease in Haplo-Identical Hematopoietic Stem Cell Transplantation Recipients With Severe Aplastic Anemia

This systematic review and meta-analysis evaluates the efficacy of MSCs as prophylaxis for GVHD in SAA patients with haplo-HSCT.

Stem Cell Research & Therapy
02/04/2021
Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation

Recently, programmed cell death 1(PD-1) inhibitors have shown a significant curative effect in the treatment of most solid cancers and some hematological malignancies.

OncoTargets and Therapy
02/10/2021
Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease

This review summarizes the evidence from these monogenic immune related diseases that provide insight into pathogenic pathways in chronic GvHD, rationales for current therapies and...

Frontiers in Immunology
02/04/2021
A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease

This study investigates whether the detection of a combination of the expression of T-cell surface markers on peripheral blood CD8+ T-cells would improve the ability to predict aGvHD.

Frontiers in Immunology
01/29/2021
Sitagliptin Reduced Graft-Versus-Host Disease in Stem Cell Transplantation

A phase II clinical study found a big reduction in acute GVHD after adding the dipeptidyl peptidase-4 inhibitor sitagliptin to immunosuppression therapy for allogeneic stem cell transplantation.

Oncology Times - Latest Articles
02/05/2021
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD

Severe AGVHD is a major cause of death after unrelated-donor hematopoietic cell transplant, resulting in particularly high mortality after HLA-mismatched transplantation.

Journal of Clinical Oncology
01/15/2021
Human Amnion-Derived Mesenchymal Stem Cells Attenuate Xenogeneic Graft-versus-Host Disease by Preventing T Cell Activation and Proliferation

Due to their immunosuppressive properties, mesenchymal stem cells have been increasingly examined for the treatment of immune-related diseases.

Scientific Reports
01/28/2021
Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

In this study, monotherapy with ruxolitinib is associated with a meaningful response in patients with steroid-refractory chronic GvHD, suggesting a possible therapeutic option...

01/27/2021
Nephrotic Syndrome in Syngeneic Hematopoietic Stem Cell Transplantation Recipients

Complications after transplantation, such as acute and chronic GVHD, still seriously affect the quality of life and even threaten the lives of patients.

01/26/2021
Relapsed Chronic Lymphocytic Leukaemia with Concomitant Extensive Chronic Graft versus Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation Successfully Treated with Oral Venetoclax

This case highlights challenges in managing relapsed CLL and loss of graft-versus-leukaemia effect despite extensive chronic GVHD.

01/22/2021
Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease

This study investigates how the stress responsive heme catabolizing enzyme heme oxygenase-1 regulates GVHD in response to allogeneic HSCT in mice and humans.

Frontiers in Immunology
01/18/2021
Addition of Abatacept to Acute Graft-vs-Host Disease Prophylaxis

Watkins et al found that the addition of T-cell costimulation blockade with abatacept to CNI/MTX–based graft-vs-host disease prophylaxis resulted in reduced rates...

The ASCO Post
01/29/2021
Chronic Graft-vs-Host Disease: Future Directions in Treatment

HSCT has improved survival rates for several hematologic malignancies, but as the number of transplants continues to rise, community oncologists are evaluating more...

The ASCO Post
01/25/2021
Unmasking Viral Sequences by Metagenomic Next-Generation Sequencing in Adult Human Blood Samples During Steroid-Refractory/Dependent Graft-versus-Host Disease

Allo-HSCT recipients with steroid-refractory/dependent GvHD are highly immunosuppressed and are more vulnerable to infections with weakly pathogenic or commensal viruses.

01/24/2021

Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease

01/27/2021
Development of Acoustically Isolated Extracellular Plasma Vesicles for Biomarker Discovery in Allogeneic Hematopoietic Stem Cell Transplantation

Study investigators examine if EVs isolated by novel automated acoustic trapping could be developed as potential biomarkers for allo-HSCT complications by performing a clinical proof-of-principle s

01/19/2021
The Adverse Events of Haematopoietic Stem Cell Transplantation are Associated With Gene Polymorphism Within Human Leukocyte Antigen Region

This study investigates the correlation between the gene polymorphisms within the HLA region and the adverse reactions of post-HSCT in patients with acute leukaemia...

Scientific Reports
01/14/2021
Comparison of Alemtuzumab, Anti-Thymocyte Globulin, and Post-Transplant Cyclophosphamide for Graft-versus-Host Disease and Graft-versus-Leukemia in Murine Models

This study examines whether these drugs could ameliorate GvHD without diminishing the graft-versus-leukemia effect by using a xenogeneic transplanted GvHD/graft-versus-leukemia model.

PLOS ONE
01/11/2021
Diabetes Drug Reduces Acute GVHD After Stem Cell Transplant

A new study shows that adding the diabetes drug sitagliptin to usual immunsuppression therapies substantially reduces the risk for this adverse event.

Medscape
01/13/2021
A Qualitative Exploration of Quality of Life Issues in Individuals With Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant and Their Experiences of a Specialist Multidisciplinary Bone Marrow Transplant Service

This study conducts a primary explorative qualitative study of the experience of QOL issues and multidisciplinary care in patients with chronic GVHD following allogeneic stem cell transplantation. 

01/07/2021
Longitudinal Dynamics of Gut Bacteriome, Mycobiome and Virome after Fecal Microbiota Transplantation in Graft-versus-Host Disease

This study reports longitudinal dynamics of the gut bacteriome, mycobiome and virome in a teenager with GvHD after receiving four doses of FMT at weekly interval.

01/04/2021
Feasibility of Reduced-Dose Posttransplant Cyclophosphamide and Cotransplantation of Peripheral Blood Stem Cells and Umbilical Cord-Derived Mesenchymal Stem Cells for SAA

Posttransplant cyclophosphamide as GVHD prophylaxis is an effective strategie for patients receiving MSD-HSCT and haplo-HSCT.

Scientific Reports
01/08/2021
Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease.

This study describes the economic burden associated with cGVHD.

European Journal of Health Economics
12/04/2020
Spatio-Temporal Bone Remodeling after Hematopoietic Stem Cell Transplantation

The interaction of hematopoietic cells and the bone microenvironment to maintain bone homeostasis is increasingly appreciated.

International Journal of Molecular Sciences
12/29/2020
Graft-vs-Host Disease After Liver Transplantation: A Diagnostic and Management Challenge

This study presents a case of GVHD in liver transplant and our treatment experience with novel immunotherapeutic agents.

12/21/2020
Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease

The main goal of this review is to identify potential novel biomarkers for cGvHD besides the widely accepted molecular and cellular biomarkers.

Frontiers in Immunology
01/23/2021
COVID-19 and graft-versus-host disease: a tale of two diseases (and why age matters)

A hypothesis is herein advanced that, as with aGVHD, lung stem cell targeting is a potential co-factor in explaining age-related severity of COVID-19 infection.

12/09/2020
Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome

The effect of telomere length on NRM was most prominent after higher intensity conditioning and in patients with severe acute graft-versus-host disease.

 

Blood
12/24/2020
Tear proteomic profile in three distinct ocular surface diseases: keratoconus, pterygium, and dry eye related to graft-versus-host disease

This study aimed to evaluate tear proteomic profile in 3 distinct ocular diseases: keratoconus, severe dry eye related to GvHD and pterygium.

12/07/2020
Key Metabolic Pathways in MSC-Mediated Immunomodulation: Implications for the Prophylaxis and Treatment of Graft Versus Host Disease

MSCs have been employed as a cellular immunotherapy in diverse preclinical models and clinical trials, but most commonly as agents for the prophylaxis or therapy of GvHD after...

Frontiers in Immunology
12/07/2020
Myeloid-derived suppressor cells therapy enhance immunoregulatory properties in acute graft versus host disease with combination of regulatory T cells

Cell-based therapy for acute graft-versus-host disease may enable induction of donor-specific tolerance in the preclinical setting.

12/14/2020
Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes

This study explored the efficacy of low-dose rabbit antithymocyte globulin in MSD-HSCT for patients with acute leukemia or myelodysplastic syndrome.

11/30/2020
Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease

The objective of this study was to describe the harm outcomes reported among patients receiving second- and third-line treatment as part of the management for GvHD...

12/08/2020
Preclinical Studies of MSC-Derived Extracellular Vesicles to Treat or Prevent Graft Versus Host Disease: a Systematic Review of the Literature.

Treating and preventing GVHD after allogeneic HCT remains a significant challenge.The use of mesenchymal stromal cell-derived extracellular vesicles appears...

Stem Cell Reviews and Reports
11/07/2020
Female urethral stricture from chronic graft-versus-host disease

Female urethral strictures are rare with limited literature to guide management. This study presents a case of a 27 year old female diagnosed with a urethral stricture secondary...

Urology case reports
11/07/2020
Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.

The purpose of this study is to identify the efficacy of ruxolitinib in HLA haplo-HSCT recipients with multidrug-resistant (MDR)-graft-versus-host disease...

Annals of Hematology
11/07/2020
The role of the microbiome in the pathogenesis and severity of GvHD

Intestinal microbiota is thought to play a role as a modulator in the pathophysiology of GvHD, via stimulation and differentiation of donor T cells or consequent innate immune-inflammatory mediator

11/16/2020
Multiple strictures of the small intestine demanding surgical intervention as a rare consequence of graft versus host disease – case report

Intestinal strictures are an extremely rare and life-threatening complication in patients undergoing allogenic hematopoietic stem cell transplantation.

Annals of Pediatric Surgery
12/01/2020
Effect of Remestemcel-L Treatment in Pediatric Steroid Refractory Acute Graft-Versus-Host Disease: A Biomarker Substudy

The aim of the biomarker substudy was to explore the effect of remestemcel-L treatment on biomarkers involved in disease processes in aGVHD and which have established...

Blood
11/05/2020
New Biomarker May Help Identify Patients at Risk for Graft-Versus-Host Disease

This report sheds light on immune cell biomarkers that may reveal which patients are most at risk for GVHD, a life-threatening condition that can arise after HSCT for treatment of...

Oncology Times - Latest Articles
11/05/2020
Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis: A Retrospective Study of 223 Cases

Pre-transplant comorbidities, which may impact the success of allogeneic stem cell transplantation can be appreciated through 3 different scoring systems.

Blood
11/05/2020
Real World Experience of Etanercept in Steroid Refractory Acute Graft Versus Host Disease from a Tertiary Cancer Centre in India

This study investigates the experience with etanercept as the initial agent in SR aGVHD.

Blood
11/05/2020
Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT

This study investigated the clinical efficacy of ruxolitinib and its safety profile in patients having SR-cGVHD after allo-SCT during the treatment course.

Blood
11/05/2020
Use of Prebiotics as GvHD Prophylaxis

In a single-center, case-controlled study, the authors investigated the impact of prebiotic administration prior to conditioning for allo-HSCT through to Day 28, on the development of mucositis...<

11/05/2020
Consensus reached on initial treatment of acute graft-versus-host disease in patients who receive bone marrow transplant; nothing definitive yet for secondary treatment

Dr. Jeanne Palmer discusses treatments for bone marrow transplant patients with acute graft-versus-host disease.

10/09/2020
Restoration of gut microbial diversity by donor FMT could resolve GI GvHD

The critical role of gut microbiota in GI GvHD and the potential of donor fecal microbiota transplantation has been previously suggested based on clinical data.

11/11/2020
CD4+ T-cell reconstitution predicts Survival Outcomes after acute Graft-versus-Host-Disease; a dual center validation

In this retrospective analysis, it is demonstrated that early CD4+ IR is associated with survival after moderate to severe aGvHD.

Blood
11/04/2020
Pomalidomide in Chronic GvHD – Efficacy and Safety

In this single-center, randomized phase II trial, the authors investigated the safety and efficacy of pomalidomide in treating moderate to severe cGvHD refractory to prior therapies and...

11/05/2020
Preventing transfusion‐associated graft‐versus‐host disease with blood component irradiation: indispensable guidance for a deadly disorder

TA‐GvHD is a rare but largely fatal complication of transfusion characterized by fever, rash, diarrhea, hepatitis and pancytopenia 2–30 days after transfusion.

08/01/2020
Lysosomal Acid Lipase Is Required for Donor T Cells to Induce Graft-versus-Host Disease

This study reveals the role of LAL in T cell alloresponse and pathogenicity and validates LAL as a target for controlling GVHD and tumor relapse after allo-HCT.

10/27/2020

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39